Persistent vulvar burning, tenderness, and pain with penetration can be difficult to resolve, particularly when patients have already tried multiple treatments. Vulvodynia is not a single disease process, and patients with similar symptoms may have very different contributing factors.
For clinicians, identifying where pain occurs and what may be driving it is essential. Good Clean Rx offers a broader range of localized prescription therapies to support individualized, multimodal vulvar pain management.
Understanding the Different Contributors to Vulvar Pain
Vulvodynia is defined as vulvar pain lasting at least three months without a clearly identifiable cause. Pain may be localized to the vestibule, generalized across the vulva, provoked by touch, or spontaneous.
Evaluation begins with symptom history, tissue examination, gentle cotton-swab pain mapping, and assessment of pelvic floor tenderness. Hormonal changes, inflammatory conditions, pelvic floor dysfunction, and altered pain signaling may contribute independently or together.
These distinctions matter because treatment directed at one contributor may not adequately address another.
A Multimodal Approach to Treatment
Effective management often combines tissue care, local symptom relief, pelvic floor rehabilitation, and treatment of underlying inflammatory conditions.
Pelvic floor physical therapy has particularly strong supporting evidence for provoked vestibulodynia. In a randomized clinical trial, multimodal physical therapy improved pain and sexual function, with benefits maintained at six months.
Local medications offer additional options when pain persists. Lidocaine and pramoxine can provide temporary relief, while topical gabapentin has shown potential benefit in observational studies of vulvodynia.
Good Clean Rx includes local anesthetic combinations, gabapentin formulations, and clinician-directed naltrexone preparations. Evidence for compounded topical agents varies, making individualized prescribing and follow-up important.
Exploring Mast Cell–Directed Therapies
Growing interest in vulvodynia research centers on interactions among mast cells, inflammatory mediators, and sensory nerves in vestibular tissue.
Ketotifen, an antihistamine with mast cell-stabilizing activity, is being investigated as a potential treatment. An ongoing randomized, placebo-controlled trial is evaluating ketotifen 0.25% cream for secondary provoked vestibulodynia.
Good Clean Rx offers ketotifen creams and suppositories, including combinations with gabapentin, pramoxine, or sodium hyaluronate. Cromolyn-based formulations provide another mast cell-directed option.
These approaches are promising areas of investigation, although clinical efficacy in vulvodynia remains to be established.
Addressing Inflammatory Vulvar Conditions
Not all persistent vulvar pain is vulvodynia. Conditions such as lichen sclerosus require treatment of the underlying inflammatory disease.
Topical corticosteroids remain established therapies for lichen sclerosus, while tacrolimus may be considered in selected circumstances. Good Clean Rx offers mometasone, clobetasol, and tacrolimus formulations for clinician-directed care.
Why Formulation Matters
Vulvar and vestibular tissues can be particularly sensitive to topical ingredients and medication vehicles.
Good Clean Rx incorporates BiomeNourish™, a proprietary pH-balanced, iso-osmolar cream base designed specifically for vulvovaginal tissue compatibility. The formulation approach considers the tissue receiving treatment alongside the active ingredient.
Bringing More Options Into Clinical Practice
Good Clean Rx brings localized pain therapies, anti-inflammatory formulations, moisture support, and individualized compounding into one prescriber platform.
The goal is to help clinicians match treatment to the patient's pain pattern, tissue findings, and contributing factors rather than relying on a single approach.
Explore the Good Clean Rx formulary and companion IVH clinical education resources through the prescriber platform.
Selected References
-
Morin M, et al. Multimodal physical therapy versus topical lidocaine for provoked vestibulodynia. Am J Obstet Gynecol. 2021;224:189.e1–189.e12.
-
Boardman LA, et al. Topical gabapentin in localized and generalized vulvodynia. Obstet Gynecol. 2008;112:579–585.
-
Sullender RT, et al. Low-dose naltrexone as a treatment for vulvodynia: a case series. Case Rep Womens Health. 2025;45.
-
Centers for Vulvovaginal Disorders. Clinical trial of ketotifen fumarate 0.25% cream.
-
Kirtschig G, et al. Evidence- and consensus-based guideline on lichen sclerosus. J Dtsch Dermatol Ges. 2026;24:566–584.